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It is now well established that a high blood pressure (BP) that can not be normal-
ized by nonpharmacologic means (low salt diet, weight loss, exercise, smoking cessa-
tion), should be treated pharmacologically. The therapeutic target BP is still a moving 
target, as in the past it used to be 160/95 mmHg. However, nowadays most guidelines 
accept the epidemiologic target of 140/90 for the general population, whereas a lower 
target of 130/80 is desirable for high risk populations, such as diabetics or patients 
with chronic renal insufficiency. However, a really “normal” BP is now believed to 
be 120/80 mmHg, because evidence from numerous observational studies (such as 
the Framingham Heart Study) and interventional long-term outcome trials indicates 
that even small increases in BP above this level are associated with a linear increase 
in risk of cardiovascular and cerebrovascular complications.
Whereas there is general agreement that lowering BP to target is the first and 
most important consideration, there is still ongoing debate as to what should be the 
first choice approach. There are six broad classes of antihypertensive drugs available 
today. The older agents are diuretics (including distal and loop diuretics), sympatholytic 
agents (including â-adrenergic blockers, á-adrenergic blockers and central sympathetic 
suppressants) and direct vasodilators (such as hydralazine and minoxidil); the newer 
classes are calcium channel blockers (CCB’s), angiotensin-converting enzyme inhibi-
tors (ACEI’s) and angiotensin receptor blockers (ARB’s).
The earlier clinical trials that produced incontrovertible evidence of benefit in 
terms of end organ protection from antihypertensive therapy, used mostly combina-
tions of thiazide diuretics with sympatholytics—mostly â-blockers. Interestingly, the 
results revealed significant decreases in rates of strokes, renal failure and heart failure, 
but only marginal and inconsistent decreases in coronary artery disease. A possible 
explanation for this was suggested by subsequent clinical studies that described the 
side-effects of these classes: the most important seems to be aggravation of insulin 
resistance (which is already a characteristic of untreated essential hypertension and 
normal aging), resulting in hyperinsulinemia, hyperglycemia, dyslipidemia, i.e. com-
ponents of what is now called the “cardiometabolic syndrome.” Each one of these 
components, along with other metabolic disturbances that accompany diuretic therapy, 
such as hypokalemia, hyperuricemia and, not least, stimulation of the renin-angio-
tensin system, represent additional coronary risk factors that tend to partly offset the 
benefits of BP lowering.
By contrast, the newer classes of antihypertensive drugs are devoid of such ad-
verse effects: The CCB’s are metabolically neutral, whereas the ACEI’s and ARB’s 
are metabolically beneficial, as they tend to restore insulin sensitivity and minimize 
metabolic aberrations. Indeed, in most comparative trials, the relative risk of new onset 
type 2 diabetes is diminished by about 18-20% with CCB’s and 35-40% by ACEI’s 
compared to thiazides.
So why is there still a debate regarding what should be the drug(s) of first choice? 
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Two reasons: One is that the largest NIH-supported trial, the 
Antihypertensive and Lipid Lowering treatment to prevent 
Heart Attack Trial (ALLHAT), showed that patients on 
diuretic therapy had a significantly better BP control, lesser 
incidence of strokes and no difference in incidence of coronary 
events compared to patients on ACEI. Critics counteract that 
the study was poorly designed as it had a large proportion of 
black patients who respond to diuretics, but not to ACEI’s, 
hence the ACEI group had significantly higher BP’s through-
out, hence more strokes and yet, not more coronary events, 
hinting at cardioprotection by the ACEI.
The second is the theory that drug-induced diabetes is 
somehow “benign” and should not be a deterrent, since pa-
tients who became diabetics during drug trials suffered a lot 
fewer cardiovascular events that patients who were already 
diabetics upon entering the trial. Critics counteract that these 
differences are quantitative, as they reflect a shorter duration 
of newly diabetic patients’ follow-up rather than qualitative 
differences in diabetic status; indeed new onset diabetes would 
be expected to produce complications at a later stage, beyond 
the specific trials’ follow-up period.
So common sense dictates that the first choice antihyper-
tensive should be one that offers the best metabolic profile 
(usually an ACEI or ARB), but additional agents should be 
used as needed to attain optimal BP control (usually a diuretic 
or CCB or both), whereas â-blockers should be used only 
if specially indicated for co-morbidities, such as in cases of 
coexisting coronary disease or chronic heart failure.
R E F E R E N C E S
 1. Whelton PK, Barzilay J, Cushman WC, Davis BR; ALLHAT 
Collaborative Research Group. Clinical outcomes in anti-
hypertensive treatment of type 2 diabetes, impaired fasting 
glucose concentration, and normoglycemia: Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT). Arch Intern Med 2005; 165:1401-9.
 2. Rahman M, Pressel S, Davis BR, Nwachuku C, et al. Renal 
outcomes in high-risk hypertensive patients treated with an 
angiotensin-converting enzyme inhibitor or a calcium chan-
nel blocker vs a diuretic: a report from the Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT). Arch Intern Med 2005;165:936-46.
 3. Moser M. Update on the management of hypertension: recent 
clinical trials and the JNC 7. J Clin Hypertens (Greenwich). 
2004; 6(10 Suppl 2):4-13.
 4. Epstein M, Campese VM. Evolving role of calcium antagonists 
in the management of hypertension. Med Clin North Am 2004; 
88:149-65.
 5. Ibrahim MM. RAS inhibition in hypertension. J Hum Hyper-
tens 2006; 20(2):101-8.
 6. Kjeldsen SE, Lyle PA, Tershakovec AM, Devereux RB, et al. 
Targeting the renin-angiotensin system for the reduction of 
cardiovascular outcomes in hypertension: angiotensin-con-
verting enzyme inhibitors and angiotensin receptor blockers. 
Expert Opin Emerg Drugs 2005; 10(4):729-45.
 7. Silverstein RL, Ram CV. Angiotensin-receptor blockers: ben-
efits beyond lowering blood pressure. Cleve Clin J Med 2005; 
72(9):825-32.
 8. Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr. Angiotensin-
converting enzyme inhibitors or angiotensin receptor blockers 
for prevention of type 2 diabetes: a meta-analysis of random-
ized clinical trials. J Am Coll Cardiol 2005; 46(5):821-6.
 9.  Cheung BM, Cheung GT, Lauder IJ, Lau CP, Kumana CR. 
Meta-analysis of large outcome trials of angiotensin receptor 
blockers in hypertension. J Hum Hypertens 2006; 20(1):37-43.
 10.  Elliott WJ. Cardiovascular events in hypertension trials of 
angiotensin-converting enzyme inhibitors. J Clin Hypertens 
(Greenwich). 2005; 7(8 Suppl 2):2-4.
